Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer

Inclusion Criteria: * COHORT 1: LUNG CANCER PATIENTS * Pathologically confirmed bronchogenic lung carcinoma (small cell lung cancer \[SCLC\] or non-small cell lung cancer \[NSCLC\] of any stage) at any treatment time point * For individuals diagnosed with advanced disease (stage IV or recurrent) enrollment must occur within 2 years of diagnosis * For appropriate patients (stage IV non-squamous NSCLC) epidermal growth factor receptor (EGFR ) and anaplastic lymphoma kinase (ALK) genotyping performed by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory is recommended prior to participation * Provision of written informed consent * Willingness to undergo a single blood draw * Individuals who are under 18 are eligible for study if they meet the defined criteria for cohort 1; in addition, consent for participation must be given by a legal guardian or parent * NOTE: to be eligible for genomics, availability of 10 unstained slides (plus hematoxylin and eosin \[H\&E\] slide) or an adequate formalin-fixed paraffin-embedded (FFPE) tumor block from clinically indicated interventional procedures is required * COHORT 2: DECEASED INDIVIDUALS * Deceased individuals diagnosed with lung cancer at any age less than 40 may be studied on a case by case basis depending upon Institutional Review Board (IRB) approval at a participating institution; inclusion will require availability of adequate archived FFPE tissue and release of tissue and records by next of kin, if available Exclusion Criteria: * Compromise of patient diagnosis or staging if tissue is used for research